Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models

por Reder, Anthony T.
Publicado 2023

Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology

por Reder, Anthony T., Feng, Xuan
Publicado 2013

Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug

por Javed, Adil, Reder, Anthony T.
Publicado 2016

Immunomodulatory activity of interferon-beta

por Kasper, Lloyd H, Reder, Anthony T
Publicado 2014

Vitamin D and Multiple Sclerosis: A Comprehensive Review

por Sintzel, Martina B., Rametta, Mark, Reder, Anthony T.
Publicado 2017

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

por Hunter, Samuel F., Bowen, James D., Reder, Anthony T.
Publicado 2015

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

por Reder, Anthony T, Stuve, Olaf, Tankou, Stephanie K, Leist, Thomas P
Publicado 2022

Effective treatment of CLIPPERS with long-term use of rituximab

por Cipriani, Veronica P., Arndt, Nancy, Pytel, Peter, Reder, Anthony T., Javed, Adil
Publicado 2018

Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles

por Fong, Chloe C., Spencer, Julian, Howlett-Prieto, Quentin, Feng, Xuan, Reder, Anthony T.
Publicado 2023

Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles

por Fong, Chloe C., Spencer, Julian, Howlett-Prieto, Quentin, Feng, Xuan, Reder, Anthony T.
Publicado 2023

Vitamin D enhances responses to interferon-β in MS

por Feng, Xuan, Wang, Zhe, Howlett-Prieto, Quentin, Einhorn, Nathan, Causevic, Suad, Reder, Anthony T.
Publicado 2019

Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection

por Feng, Xuan, Bao, Riyue, Li, Lei, Deisenhammer, Florian, Arnason, Barry G.W., Reder, Anthony T.
Publicado 2019

Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment

por Poulos, Christine, Kinter, Elizabeth, Yang, Jui-Chen, Bridges, John F. P., Posner, Joshua, Reder, Anthony T.
Publicado 2015

Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS

por Goodin, Douglas S., Jones, Jason, Li, David, Traboulsee, Anthony, Reder, Anthony T., Beckmann, Karola, Konieczny, Andreas, Knappertz, Volker
Publicado 2011

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment

por Koskimäki, Fredrika, Bernard, Jacqueline, Yong, Jeong, Arndt, Nancy, Carroll, Timothy, Lee, Seon-Kyu, Reder, Anthony T., Javed, Adil
Publicado 2018

Increased Percentage of CD8(+)CD28(−) Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis

por Houston, Timothy W., Howlett-Prieto, Quentin, Regenauer, Colin, Testai, Fernando D., Yao, Faith, Feng, Xuan, Reder, Anthony T.
Publicado 2022

Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients

por Telesford, Kiel M., Amezcua, Lilyana, Tardo, Lauren, Horton, Lindsay, Lund, Brett T., Reder, Anthony T., Vartanian, Timothy, Monson, Nancy L.
Publicado 2023

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

por Cohan, Stanley L., Hendin, Barry A., Reder, Anthony T., Smoot, Kyle, Avila, Robin, Mendoza, Jason P., Weinstock-Guttman, Bianca
Publicado 2021

Interferonβ-1b Induces the Expression of RGS1 a Negative Regulator of G-Protein Signaling

por Tran, Tiffany, Paz, Pedro, Velichko, Sharlene, Cifrese, Jill, Belur, Praveen, Yamaguchi, Ken D., Ku, Karin, Mirshahpanah, Parham, Reder, Anthony T., Croze, Ed
Publicado 2010

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

por Weinstock-Guttman, Bianca, Bermel, Robert, Cutter, Gary, Freedman, Mark S, Leist, Thomas P, Ma, Xiaoye, Kile, Deidre, Musch, Bruno, Reder, Anthony T, Wolinsky, Jerry S
Publicado 2021